8-K: Corbus Pharmaceuticals Announces Promising Phase 1 Data for CRB-701 at ASCO-GU 2025, Expanding Potential in HNSCC

Corbus Pharmaceuticals reports encouraging safety and efficacy data from its Phase 1 trial of CRB-701 (SYS6002), a next-generation Nectin-4 targeting ADC, including notable responses in head and neck squamous cell carcinoma (HNSCC).

Summary

• Corbus Pharmaceuticals announced data from its Phase 1 dose escalation clinical trial for SYS6002 (CRB-701) at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU).
• The Western study, conducted in the US and UK, enrolled patients with metastatic urothelial cancer (mUC) and other solid tumors associated with Nectin-4 expression.
• The study included tumor types not previously explored in the China study conducted by CSPC Pharmaceutical Group.
• The Western study enrolled 38 participants, with 26 evaluable for efficacy, across the top four dose cohorts used in China (1.8, 2.7, 3.6, and 4.5 mg/kg) following a Q3W regimen.
• No dose-limiting toxicities were observed in either the Western or China studies.
• CRB-701 was well-tolerated, with most treatment-emergent adverse events being grade 1 or 2.
• The Western study implemented a proactive ocular toxicity protocol, resulting in a lower incidence of ocular adverse events (38%) compared to the China study (66%) at the 2.7 mg/kg and 3.6 mg/kg doses.
• The PK profile in the Western study was comparable to the China study, with CRB-701 demonstrating a longer ADC half-life and lower free-MMAE exposure relative to enfortumab vedotin (EV).
• Responses were observed in several tumor types, including HNSCC, mUC, and cervical cancer.
• In the Western study, mUC patients (n=4) showed 1 PR, 1 SD, and 2 PD, while the China study (n=9) had an ORR of 44%.
• Cervical cancer patients in the Western study (n=2) had 1 CR and 1 PD, while the China study (n=7) had an ORR of 43%.
• HNSCC patients in the Western study (n=7) showed 4 PR, 2 SD, and 1 PD.
• The Western study did not have a Nectin-4 IHC threshold for inclusion, and responses were observed in participants with low H-scores for Nectin-4.
• Dose optimization is underway with dosing at 2.7 mg/kg and 3.6 mg/kg Q3W in HNSCC, cervical, and mUC tumors.

Sentiment

Score: 8

Explanation: The document presents positive Phase 1 data with encouraging safety and efficacy signals, particularly in HNSCC, suggesting potential for future clinical development and market opportunity. The proactive management of ocular toxicity and favorable PK profile further contribute to a positive outlook.

Positives

• CRB-701 demonstrated a favorable safety profile with no dose-limiting toxicities.
• The proactive ocular toxicity protocol significantly reduced ocular adverse events in the Western study.
• Clinical responses were observed in multiple tumor types, including HNSCC, mUC, and cervical cancer.
• The study showed efficacy even in tumors with low Nectin-4 expression.
• CRB-701 has a longer ADC half-life and lower free-MMAE exposure compared to enfortumab vedotin (EV).
• A HNSCC patient with resistant disease showed clinical improvement with CRB-701 treatment.

Negatives

• Two mUC patients in the Western study experienced progressive disease (PD) after prior treatment with enfortumab vedotin (EV).
• One cervical cancer patient in the Western study experienced progressive disease (PD).
• Skin and subcutaneous disorders were more frequent in the Western study (24%) compared to the China study (8%).

Risks

• The Phase 1 data is preliminary and requires further validation in larger, controlled trials.
• The efficacy of CRB-701 may vary depending on prior treatments and individual patient characteristics.
• The higher incidence of skin and subcutaneous disorders in the Western study warrants further investigation.
• The long-term safety and efficacy of CRB-701 need to be established.

Future Outlook

Corbus is proceeding with dose optimization of CRB-701 in HNSCC, cervical, and mUC tumors, and is planning dose expansion at RP2D. The company is also advancing CRB-601 and CRB-913 through clinical development.

Management Comments

• 'I am encouraged by this emerging clinical data and its similarity to what has already been established for CRB-701 in China by our partner CSPC,' stated Dominic Smethurst, Chief Medical Officer of Corbus.
• 'It is gratifying to see that the differentiated safety and tolerability profile has been replicated as have the efficacy signals in both mUC and cervical cancers.'
• 'A new, previously unexplored potential benefit in HNSCC provides further impetus for us to continue the clinical development of this novel, differentiated ADC.'

Industry Context

The development of CRB-701 as a next-generation Nectin-4 targeting ADC addresses the need for improved tolerability and reduced cumulative toxic effects compared to existing therapies like enfortumab vedotin (Padcev). The exploration of HNSCC as a potential target expands the application of Nectin-4 targeted therapies.

Comparison to Industry Standards

• CRB-701 shows a favorable safety profile compared to Padcev, BT8009, and 9MW-2821, with lower rates of peripheral neuropathy, rash, and dose modifications.
• CRB-701 demonstrated a longer ADC half-life and lower free-MMAE exposure relative to enfortumab vedotin (EV).
• In HNSCC, CRB-701's ORR of 4 out of 7 patients compares favorably to late-stage/rescue therapies like Methotrexate (4%), Cetuximab (11%), and Paclitaxel (14%).
• The ORR of 42% across HNSCC, CC & mUC patients in US-UK/China compares favorably to other therapies.

Stakeholder Impact

• Shareholders: Positive data may increase investor confidence and potentially lead to higher stock value.
• Patients: Promising efficacy in multiple tumor types offers potential new treatment options.
• Employees: Advancement of clinical programs may provide job security and growth opportunities.
• Partners: Collaboration with CSPC Pharmaceutical Group is strengthened by positive data.

Next Steps

• Continued dose optimization of CRB-701 in HNSCC, cervical, and mUC tumors.
• Dose expansion at RP2D.
• Initiation of Phase 1b study for CRB-913 in Q4-2025.
• Completion of Phase 1 dose escalation for CRB-701 in Q4-2025.
• Completion of dosing under Project Optimus and establishment of RP2D in Q4-2025.
• Dose first patient in Ph1 SAD/MAD for CRB-913 in Q1-2025.

Key Dates

Keywords

CRB-701, SYS6002, Nectin-4, ADC, Antibody-Drug Conjugate, HNSCC, mUC, Urothelial Cancer, Cervical Cancer, ASCO GU, Phase 1 Trial, Corbus Pharmaceuticals, Oncology